Dosing Initiated in a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Chronic ...

Enanta Pharmaceuticals, Inc. , a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the Company will ...

AbbVie Inc. ABBV reported first-quarter 2026 adjusted EPS of $2.65, which beat the Zacks Consensus Estimate of $2.62. The reported figure also exceeded the company’s guidance of $2.56-$2.60 issued ...

The president’s executive order is intended to accelerate research into the compounds’ efficacy in treating mental health disorders like severe depression and PTSD. By Andrew Jacobs and Noah Daly ...

President Trump has signed an executive order to ease research restrictions on psychedelics, including the drug ibogaine, which is used in some countries to treat post-traumatic stress disorder.

President Donald Trump on Saturday directed his administration to speed up reviews of certain psychedelic drugs, including ibogaine, which recently has been embraced by combat veterans and ...

The hotel ballroom was packed to near capacity with scientists when Susan Yanovski arrived. Despite being 10 minutes early, she had to manoeuvre her way to one of the few empty seats near the back.

On April 18, President Donald Trump signed an executive order intended to accelerate the development of psychedelic drugs as medical treatments. The order calls for the Food and Drug Administration ...

President Donald Trump on Saturday directed his administration to speed up reviews of certain psychedelic drugs, including ibogaine, which recently has been embraced by combat veterans and ...

REMOVING BARRIERS TO PSYCHEDELIC DRUGS AS POTENTIAL TREATMENT FOR SERIOUS MENTAL ILLNESS: Today, President Donald J. Trump signed an Executive Order that will accelerate access to treatments for ...

Drug discovery and development together are the complete process of identifying a new drug and bringing it to market. Discovery may involve screening of chemical libraries, identification of the ...

Reports First-Quarter Diluted EPS of $0.39 on a GAAP Basis, a Decrease of 45.8 Percent; Adjusted Diluted EPS of $2.65, an Increase of 7.7 Percent; These Results Include ...